{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T22:17:42Z","timestamp":1776723462471,"version":"3.51.2"},"reference-count":41,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"European Alliance of Associations for Rheumatology"}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2022,5]]},"DOI":"10.1136\/annrheumdis-2021-221490","type":"journal-article","created":{"date-parts":[[2021,12,31]],"date-time":"2021-12-31T19:10:15Z","timestamp":1640977815000},"page":"695-709","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":150,"title":["Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry"],"prefix":"10.1016","volume":"81","author":[{"given":"Pedro M","family":"Machado","sequence":"first","affiliation":[]},{"given":"Saskia","family":"Lawson-Tovey","sequence":"additional","affiliation":[]},{"given":"Anja","family":"Strangfeld","sequence":"additional","affiliation":[]},{"given":"Elsa F","family":"Mateus","sequence":"additional","affiliation":[]},{"given":"Kimme L","family":"Hyrich","sequence":"additional","affiliation":[]},{"given":"Laure","family":"Gossec","sequence":"additional","affiliation":[]},{"given":"Loreto","family":"Carmona","sequence":"additional","affiliation":[]},{"given":"Ana","family":"Rodrigues","sequence":"additional","affiliation":[]},{"given":"Bernd","family":"Raffeiner","sequence":"additional","affiliation":[]},{"given":"Catia","family":"Duarte","sequence":"additional","affiliation":[]},{"given":"Eric","family":"Hachulla","sequence":"additional","affiliation":[]},{"given":"Eric","family":"Veillard","sequence":"additional","affiliation":[]},{"given":"Eva","family":"Strakova","sequence":"additional","affiliation":[]},{"given":"Gerd R","family":"Burmester","sequence":"additional","affiliation":[]},{"given":"G\u00f6zde K\u00fcbra","family":"Yard\u0131mc\u0131","sequence":"additional","affiliation":[]},{"given":"Jose A","family":"Gomez-Puerta","sequence":"additional","affiliation":[]},{"given":"Julija","family":"Zepa","sequence":"additional","affiliation":[]},{"given":"Lianne","family":"Kearsley-Fleet","sequence":"additional","affiliation":[]},{"given":"Ludovic","family":"Trefond","sequence":"additional","affiliation":[]},{"given":"Maria","family":"Cunha","sequence":"additional","affiliation":[]},{"given":"Marta","family":"Mosca","sequence":"additional","affiliation":[]},{"given":"Martina","family":"Cornalba","sequence":"additional","affiliation":[]},{"given":"Martin","family":"Soubrier","sequence":"additional","affiliation":[]},{"given":"Nicolas","family":"Roux","sequence":"additional","affiliation":[]},{"given":"Olivier","family":"Brocq","sequence":"additional","affiliation":[]},{"given":"Patrick","family":"Durez","sequence":"additional","affiliation":[]},{"given":"Richard","family":"Conway","sequence":"additional","affiliation":[]},{"given":"Tiphaine","family":"Goulenok","sequence":"additional","affiliation":[]},{"given":"Johannes WJ","family":"Bijlsma","sequence":"additional","affiliation":[]},{"given":"Iain B","family":"McInnes","sequence":"additional","affiliation":[]},{"given":"Xavier","family":"Mariette","sequence":"additional","affiliation":[]}],"member":"78","reference":[{"key":"10.1136\/annrheumdis-2021-221490_bib1","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41541-021-00292-w","article-title":"SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates","volume":"6","author":"Kyriakidis","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1136\/annrheumdis-2021-221490_bib2","author":"World Health Organization"},{"key":"10.1136\/annrheumdis-2021-221490_bib3","author":"World Health Organization"},{"key":"10.1136\/annrheumdis-2021-221490_bib4","doi-asserted-by":"crossref","first-page":"1412","DOI":"10.1056\/NEJMoa2101765","article-title":"BNT162b2 mRNA Covid-19 vaccine in a nationwide mass vaccination setting","volume":"384","author":"Dagan","year":"2021","journal-title":"N Engl J Med"},{"key":"10.1136\/annrheumdis-2021-221490_bib5","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1016\/S0140-6736(21)00947-8","article-title":"Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data","volume":"397","author":"Haas","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2021-221490_bib6","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(21)00448-7","article-title":"Early rate reductions of SARS-CoV-2 infection and COVID-19 in BNT162b2 vaccine recipients","volume":"397","author":"Amit","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2021-221490_bib7","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/S0140-6736(21)00677-2","article-title":"Interim findings from first-dose mass COVID-19 vaccination roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study","volume":"397","author":"Vasileiou","year":"2021","journal-title":"Lancet"},{"key":"10.1136\/annrheumdis-2021-221490_bib8","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1038\/s41541-021-00336-1","article-title":"Comparative systematic review and meta-analysis of reactogenicity, immunogenicity and efficacy of vaccines against SARS-CoV-2","volume":"6","author":"McDonald","year":"2021","journal-title":"NPJ Vaccines"},{"key":"10.1136\/annrheumdis-2021-221490_bib9","doi-asserted-by":"crossref","first-page":"e001594","DOI":"10.1136\/rmdopen-2021-001594","article-title":"Point of view on the vaccination against COVID-19 in patients with autoimmune inflammatory rheumatic diseases","volume":"7","author":"Furer","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/annrheumdis-2021-221490_bib10","doi-asserted-by":"crossref","first-page":"e001553","DOI":"10.1136\/rmdopen-2020-001553","article-title":"Vaccination of patients with inflammatory rheumatic diseases against SARS-CoV-2: considerations before widespread availability of the vaccines","volume":"7","author":"Schulze-Koops","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/annrheumdis-2021-221490_bib11","article-title":"View points on SARS-CoV-2 vaccination in patients with RMDs","volume":"80","author":"Bijlsma","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib12","first-page":"e60-e75","article-title":"American College of rheumatology guidance for COVID-19 vaccination in patients with rheumatic and musculoskeletal diseases: version 3","volume":"73","author":"Curtis","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2021-221490_bib13","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"The REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J Biomed Inform"},{"key":"10.1136\/annrheumdis-2021-221490_bib14","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)\u2013a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris","year":"2009","journal-title":"J Biomed Inform"},{"key":"10.1136\/annrheumdis-2021-221490_bib15","author":"Centers for Disease Control and Prevention"},{"key":"10.1136\/annrheumdis-2021-221490_bib16","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1136\/annrheumdis-2020-218019","article-title":"Smart battles: immunosuppression versus immunomodulation in the inflammatory RMDs","volume":"79","author":"Isaacs","year":"2020","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib17","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1093\/rheumatology\/kex352","article-title":"Improved flare and remission pattern in rheumatoid arthritis over recent decades: a population-based study","volume":"56","author":"Raheel","year":"2017","journal-title":"Rheumatology"},{"key":"10.1136\/annrheumdis-2021-221490_bib18","article-title":"Humoral response to pfizer mRNA vaccine against SARS CoV2, in patients with autoimmune inflammatory rheumatic diseases and the impact on the rheumatic disease activity","author":"Braun-Moscovici","year":"2021","journal-title":"MedRxiv"},{"key":"10.1136\/annrheumdis-2021-221490_bib19","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/annrheumdis-2021-220231","article-title":"Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases","volume":"80","author":"Connolly","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib20","doi-asserted-by":"crossref","first-page":"1330","DOI":"10.1136\/annrheumdis-2021-220647","article-title":"Immunogenicity and safety of the BNT162b2 mRNA COVID-19 vaccine in adult patients with autoimmune inflammatory rheumatic diseases and in the general population: a multicentre study","volume":"80","author":"Furer","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib21","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1136\/annrheumdis-2021-220272","article-title":"Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort","volume":"80","author":"Geisen","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib22","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2021-220539","article-title":"Correspondence on \u2018Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort\u2018","volume":"80","author":"Ramirez","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib23","doi-asserted-by":"crossref","first-page":"1312","DOI":"10.1136\/annrheumdis-2021-220461","article-title":"SARS-CoV-2 vaccination responses in untreated, conventionally treated and anticytokine-treated patients with immune-mediated inflammatory diseases","volume":"80","author":"Simon","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib24","doi-asserted-by":"crossref","first-page":"e613","DOI":"10.1016\/S2665-9913(21)00221-6","article-title":"Tolerance of COVID-19 vaccination in patients with systemic lupus erythematosus: the International VACOLUP study","volume":"3","author":"Felten","year":"2021","journal-title":"Lancet Rheumatol"},{"key":"10.1136\/annrheumdis-2021-221490_bib25","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1136\/annrheumdis-2021-220732","article-title":"Systemic rheumatic disease flares after SARS-CoV-2 vaccination among rheumatology outpatients in New York City","volume":"80","author":"Barbhaiya","year":"2021","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib26","doi-asserted-by":"crossref","first-page":"1925","DOI":"10.1007\/s00296-021-04972-7","article-title":"Local and systemic reactogenicity of COVID-19 vaccine BNT162b2 in patients with systemic lupus erythematosus and rheumatoid arthritis","volume":"41","author":"Bartels","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1136\/annrheumdis-2021-221490_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/acr2.11336","article-title":"Incidence of disease flare after BNT162b2 coronavirus disease 2019 vaccination in patients with rheumatoid arthritis in remission","volume":"3","author":"Bixio","year":"2021","journal-title":"ACR Open Rheumatol"},{"key":"10.1136\/annrheumdis-2021-221490_bib28","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1007\/s00296-021-04917-0","article-title":"Safety of the ChAdOx1 nCoV-19 and the BBV152 vaccines in 724 patients with rheumatic diseases: a post-vaccination cross-sectional survey","volume":"41","author":"Cherian","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1136\/annrheumdis-2021-221490_bib29","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1136\/annrheumdis-2021-221252","article-title":"Temporary hold of mycophenolate augments humoral response to SARS-CoV-2 vaccination in patients with rheumatic and musculoskeletal diseases: a case series","volume":"81","author":"Connolly","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib30","article-title":"Disease flare and Reactogenicity in patients with rheumatic and musculoskeletal diseases following two-dose SARS-CoV-2 messenger RNA vaccination","author":"Connolly","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2021-221490_bib31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1136\/annrheumdis-2021-221326","article-title":"Clinical characteristics and outcomes of COVID-19 breakthrough infections among vaccinated patients with systemic autoimmune rheumatic diseases","volume":"81","author":"Cook","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib32","doi-asserted-by":"crossref","DOI":"10.55563\/clinexprheumatol\/xj2pqk","article-title":"Safety of BNT162b2 mRNA COVID-19 vaccine in a cohort of elderly, immunocompromised patients with systemic vasculitis","author":"Delvino","year":"2021","journal-title":"Clin Exp Rheumatol"},{"key":"10.1136\/annrheumdis-2021-221490_bib33","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1007\/s00296-021-05017-9","article-title":"Adverse events of six COVID-19 vaccines in patients with autoimmune rheumatic diseases: a cross-sectional study","volume":"41","author":"Esquivel-Valerio","year":"2021","journal-title":"Rheumatol Int"},{"key":"10.1136\/annrheumdis-2021-221490_bib34","article-title":"Evaluation of immune response and disease status in SLE patients following SARS-CoV-2 vaccination","author":"Izmirly","year":"2021","journal-title":"Arthritis Rheumatol"},{"key":"10.1136\/annrheumdis-2021-221490_bib35","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1038\/s41591-021-01469-5","article-title":"Immunogenicity and safety of the CoronaVac inactivated vaccine in patients with autoimmune rheumatic diseases: a phase 4 trial","volume":"27","author":"Medeiros-Ribeiro","year":"2021","journal-title":"Nat Med"},{"key":"10.1136\/annrheumdis-2021-221490_bib36","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1136\/annrheumdis-2021-221097","article-title":"BNT162b2 vaccine-induced humoral and cellular responses against SARS-CoV-2 variants in systemic lupus erythematosus","volume":"81","author":"Moyon","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib37","doi-asserted-by":"crossref","first-page":"740249","DOI":"10.3389\/fimmu.2021.740249","article-title":"ImmunosuppressiveTherapies differently modulate Humoral- and T-cell-specific responses to COVID-19 mRNA vaccine in rheumatoid arthritis patients","volume":"12","author":"Picchianti-Diamanti","year":"2021","journal-title":"Front Immunol"},{"key":"10.1136\/annrheumdis-2021-221490_bib38","doi-asserted-by":"crossref","first-page":"730","DOI":"10.3390\/vaccines9070730","article-title":"Preliminary data on post market safety profiles of COVID 19 vaccines in rheumatic diseases: assessments on various vaccines in use, different rheumatic disease subtypes, and immunosuppressive therapies: a Two-Centers study","volume":"9","author":"Rotondo","year":"2021","journal-title":"Vaccines"},{"key":"10.1136\/annrheumdis-2021-221490_bib39","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2021-001814","article-title":"Early experience of COVID-19 vaccination in adults with systemic rheumatic diseases: results from the COVID-19 global rheumatology alliance vaccine survey","volume":"7","author":"Sattui","year":"2021","journal-title":"RMD Open"},{"key":"10.1136\/annrheumdis-2021-221490_bib40","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1136\/annrheumdis-2021-221217","article-title":"SARS-CoV-2 infection after vaccination in patients with inflammatory rheumatic and musculoskeletal diseases","volume":"81","author":"Lawson-Tovey","year":"2022","journal-title":"Ann Rheum Dis"},{"key":"10.1136\/annrheumdis-2021-221490_bib41","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1186\/s12916-021-02059-5","article-title":"Evaluation of the safety profile of COVID-19 vaccines: a rapid review","volume":"19","author":"Wu","year":"2021","journal-title":"BMC Med"}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724080270?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496724080270?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/annrheumdis-2021-221490","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,20]],"date-time":"2025-01-20T04:53:27Z","timestamp":1737348807000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496724080270"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":41,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["S0003496724080270"],"URL":"https:\/\/doi.org\/10.1136\/annrheumdis-2021-221490","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2022,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety of vaccination against SARS-CoV-2 in people with rheumatic and musculoskeletal diseases: results from the EULAR Coronavirus Vaccine (COVAX) physician-reported registry","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1136\/annrheumdis-2021-221490","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2022 \u00a9 Author(s) (or their employer(s)) 2022. No commercial re-use. See rights and permissions. Published by Elsevier Inc. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}